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species (Aβ42) is formed in less amounts than Aβ40 but is more 
prone to aggregate into ﬁ  brils and makes up the major component 
of amyloid plaques. Amyloid ﬁ  brils present a dynamic nature with 
a mechanism of dissociation and re-association resulting in a recy-
cling of molecules within the ﬁ  bril population (Carulla et al., 2005). 
Plaques may not be the main contributor to neuronal death, as 
there are consistent evidences that soluble oligomeric forms of Aβ 
are strongly neurotoxic (Shankar et al., 2008). In the last 10 years, 
most of the pharmaceutical efforts have been directed against the 
production and the accumulation of Aβ, the major component of 
the amyloid plaques, with the hope of slowing the deterioration 
rate of patients (Opar, 2008).
BRAIN INFLAMMATION IN ALZHEIMER’S DISEASE
In the AD brain, degenerating neurons, deposits of aggregated 
Aβ and neuroﬁ  brillary tangles are sites of inﬂ  ammation. Amyloid 
plaques are associated with activated microglia and reactive 
astrocytosis. These cellular events are accompanied by increased 
expression of members of the complement pathway (C1q, C3b, 
C3a, membrane attack complex), cytokines and chemokines 
(interleukin-1β, interleukin-6, tumor necrosis factor α and 
INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia, 
affecting approximately 5% of the population over the age of 65. 
As the population ages, the social impact of AD is becoming more 
critical. Thus, there is an urgent need for effective pharmacologi-
cal treatments. Cholinesterase inhibitors have consistently shown 
symptomatic beneﬁ  ts and are now recognized as the standard treat-
ments in patients with mild-to-moderate AD (Doody, 2008). A 
non-competitive N-methyl-D-aspartate antagonist, memantine, is 
also available for the symptomatic treatment of moderately severe 
to severe patients (Doody, 2008). Unfortunately, neither class of 
drugs is able to halt or to slow the disease progression.
The basic pathological abnormalities in AD are amyloid plaques 
and neuroﬁ  brillary tangles. Their exact relationship is still unclear 
and how they may cause neuronal death is still an area of intense 
research effort (Small and Duff, 2008). Amyloid plaques consist 
of a proteinaceous core composed of 5–10 nm amyloid ﬁ  brils sur-
rounded by dystrophic neurites, astrocytic processes and microglial 
cells. The β-amyloid peptide (Aβ) consists of 38–42 amino acids 
generated by the cleavage of amyloid precursor protein (APP). The 
main form of Aβ contains 40 amino acids (Aβ40). The 42-residue 
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transforming growth factor β), and acute phase reactive proteins 
(α-2-macroglobulin and α1-antichymotrypsin) surrounding 
amyloid deposits. However, edema and leukocyte inﬁ  ltration is 
not observed (Weggen et al., 2007). Aggregation of soluble Aβ in 
oligomeric species can result in complement activation through 
the binding of complement molecules C1q and C3b (Figure 1). 
This activation stimulates production of C3b, membrane attack 
complex (MAC) and C3a. MAC can have toxic effects, and can 
result in cell lysis. C3b can reinforce complement activation. C3a 
activates microglial cells which can clear Aβ through phagocytosis. 
Uncleared Aβ may trigger a feedback loop in which Aβ deposition 
may be enhanced through the up-regulation of cytokines, such 
as interleukin-1β and interleukin-6, that have been reported to 
increase expression of APP (Wyss-Coray and Mucke, 2002) and to 
stimulate the synthesis of Aβ40 and Aβ42 peptides (Blasko et al., 
2000). Additionally, the inﬂ  ammation-associated proteins α1-ACT 
and apolipoprotein (ApoE) may also promote Aβ   deposition 
(Nilsson et al., 2004) (Figure 1).
FIGURE 1 | Interplay between amyloid pathology and inﬂ  ammation. Aβ is 
β-amyloid, C1q, C3b, C3a and MAC (membrane attack complex) are 
complement factors, cytokines include interleukin-1β (IL -1β), interleukin-6 (IL -6), 
tumor necrosis factor α (TNF-α) and TGF-β, ApoE is apolipoprotein E and 
α1-antichymotrypsin (α1-ACT) is an acute phase reactive protein (from Weggen 
et al., 2007).Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 19  |  3
Imbimbo et al.  NSAIDs in Alzheimer’s disease
Prevention Trial or ADAPT) (see paragraph 8). The ADAPT study 
was actually suspended prematurely because of an apparent increase 
in cardiovascular and cerebrovascular events in the naproxen arm 
compared to placebo. This event has revived the debate on the car-
diovascular safety of NSAIDs, but this time, with a special emphasis 
on the impact of non-selective COX-inhibitors on the incidence of 
cardiovascular events. The published data are quite discordant and 
one cannot conclude that there is clear evidence to support a car-
diovascular hazard from the administration of traditional NSAIDs 
like ibuprofen or naproxen (Maillard and Burnier, 2006).
EPIDEMIOLOGICAL STUDIES OF NSAIDs IN 
ALZHEIMER’S DISEASE
Several epidemiological studies, but not all studies, have evidenced 
a reduced prevalence of AD among users of NSAIDs (Table 1). The 
protective effect of NSAIDs is strongly dependent from the duration 
of treatment and on APOE genotype.
THE EFFECT OF TREATMENT DURATION
The ﬁ  rst study showing that increasing duration of NSAID use is 
associated with decreasing risk of AD was published by Stewart 
et al. (1997). They examined data from a longitudinal study of 
1,686 participants (the Baltimore < Longitudinal Study of Aging) 
and found that among subjects with two or more years of NSAID 
use, the relative risk was 0.40 compared to 0.65 for those with 
less than 2 years of NSAID use. This observation was later con-
ﬁ  rmed by several other studies. A population-based cohort study 
of 6,989 subjects found a relative AD risk of 0.95 in subjects with 
drug  short-term use (≤1 month), 0.83 in those with intermediate-
term use (1–24 months), and 0.20 in those with long-term use 
(≥24 months) (in t’ Veld et al., 2001). Pooled data from nine stud-
ies involving 14,654 subjects conﬁ  rmed that the protective effects 
depend on the duration of NSAID use with relative risks of 0.95 
among short-term (<1 month), 0.83 among intermediate-term 
(1–24 months) and 0.27 among long-term (>24 months) users 
(Etminan et al., 2003). A systematic review of seven prospective 
cohort studies found that those reporting duration of use of two or 
more years the combined risk estimate for developing AD was 0.42 
compared to 0.74 for those whom any lifetime NSAID exposure 
was reported (Szekely et al., 2004). A large case-control study in 
246,199 subjects found an adjusted odd ratio of 0.98 for ≤1 year of 
NSAID use and 0.76 for >5 years use (Vlad et al., 2008). For users of 
ibuprofen, the adjusted odd ratio decreased from 1.03 to 0.56.
The ﬁ  nding that increasing duration of NSAID use is associ-
ated with a decreasing risk of AD probably reﬂ  ects the fact that 
the long-term users are taking NSAIDs at younger ages when the 
disease process is not yet started.
THE EFFECT OF THE APOE GENOTYPE
The protective effects of NSAIDs on AD onset are strongly depend-
ent from the APOE genotype of the NSAID users. A prospective 
study (the Cardiovascular Health Cognition Study) followed for 
up to 10 years 3,229 elderly subjects (≥65 years) free of dementia at 
baseline. The study found that use of NSAIDs was associated with 
a lower risk of AD (adjusted hazard ratio of 0.63) (Szekely et al., 
2008a). AD risk reduction with NSAID was statistically signiﬁ  cant 
in subjects having an APOE ε4 allele (adjusted hazard ratio of 0.34 
CYCLOOXYGENASE INHIBITORS
The best-characterized action of NSAIDs is the inhibition of 
cyclooxygenase (COX), leading to marked reductions in the bio-
synthesis of pro-inﬂ  ammatory prostaglandins (PGs). There are at 
least two COX isoforms, COX-1 and COX-2, and each NSAID varies 
in its ability to inhibit these isoforms. COX-3 was recently described 
as a splice variant of COX-1, but its functions are unknown. COX-1 
is expressed in many tissues, and its metabolic products are consid-
ered to be involved in cellular “housekeeping” functions. COX-2 has 
lower expression levels in most tissues in healthy conditions, but 
increases during inﬂ  ammatory response. The expression levels of 
COX-1 and COX-2 change in the different stages of AD pathology 
(Hoozemans et al., 2008). In an early stage, when low Aβ deposits 
are present and only very few neuroﬁ  brillary tangles are observed 
in the cortical areas, COX-2 is increased in neurons. The increased 
neuronal COX-2 expression parallels and co-localizes with the 
expression of cell cycle proteins, suggesting that COX-2 may be 
involved in regenerating pathways. COX-1 is primarily expressed 
in microglia, which are associated with ﬁ  brillar Aβ deposits. This 
suggests that COX-1 is involved in inﬂ  ammatory pathway of the 
AD brain.
There are two classes of NSAIDs: non-selective COX-inhibitors 
and COX-2 selective inhibitors. Non-selective COX-inhibitors 
inhibit COX-1 and have variable activities against COX-2. Examples 
of non-selective COX-inhibitors are aspirin, ibuprofen, naproxen, 
piroxicam, indomethacin and sulindac. The discovery of COX-2 has 
led to the development of highly selective COX-2 inhibitors, such 
as celecoxib and rofecoxib, with the rationale that this isoform is 
inducible at the site of inﬂ  ammation whereas COX-1 is expressed 
constitutively in several tissues including gastric epithelium. COX-2 
selective inhibitors were thought to be safer for ulcerations of the 
gastro-intestinal mucosa observed with non-selective inhibitors. 
Meloxicam, nimesulide and etodolac were found as selective 
COX-2 inhibitors in pharmacological testing although they were 
not designed speciﬁ  cally as COX-2 inhibitors.
COX-2 inhibitors and some other NSAIDs have received atten-
tion because of their protective effects against colon cancer. In late 
1999 celecoxib was approved by the FDA for the prevention of colon 
cancer in patients with familial adenomatous polyposis, which is a 
hereditary precancerous disease due to a loss of the adenomatous 
polyposis coli tumor suppressor gene. Nevertheless, in September 
2004, Merck and Co announced the voluntary withdrawal of 
rofecoxib worldwide because of an increased risk of cardiovascu-
lar events. This decision and the unexpected ﬁ  ndings of a colon 
cancer study which showed that celecoxib might also increase the 
chance of heart attack and stroke in some patients, raised serious 
concerns about the safety of selective COX-2 inhibitors (Finckh 
and Aronson, 2005). The mechanism with which COX-2 inhibitors 
may increase the risk of cardiovascular events is not clear but their 
depressive effects on prostaglandin I2 formation has been advocated 
as the cause of blood pressure elevation, acceleration of athero-
genesis and exaggerated thrombotic response to the rupture of an 
atherosclerotic plaque (Fitzgerald, 2004). These ﬁ  ndings represent 
a major drawback for the clinical use of COX-2 inhibitors in gen-
eral (Couzin, 2004) and in December 2004 the FDA announced 
the suspension of a large, randomized, controlled, prevention 
trial of celecoxib in AD (Alzheimer’s Disease   Anti-inﬂ  ammatory Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 19  |  4
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of brain ﬁ  brillar Aβ than ε4-non-carriers (Reiman et al., 2009). 
Thus, it can be hypothesized that the protective effects of NSAIDs 
are more evident in APOE-ε4 carriers simply because these sub-
jects are more prone to Aβ brain deposition and accumulation and 
eventually to develop AD than ε4-non-carriers.
THE EFFECT OF AGE
Several studies have suggested that the risk reduction with NSAIDs 
decreases with age (in t’ Veld et al., 1998; Zandi et al., 2002; Szekely 
et al., 2008a). This ﬁ  nding may simply reﬂ  ect the known tendency 
of those with APOE ε4 to develop AD at younger ages. A popula-
tion-based cohort study (the Adult Changes in Thought study) in 
2,736 elderly subjects (median 74.8 years at enrolment) without 
dementia at baseline followed for up to 12 years, unexpectedly 
found that NSAID users had a signiﬁ  cant increased incidence of 
AD, with adjusted hazard ratios of 1.17 for moderate users and 1.57 
for heavy users (Breitner et al., 2009). Data on NSAIDs use was 
particularly reliable because was based on computerized pharmacy 
dispensing records. To explain these unexpected ﬁ  ndings, Authors 
hypothesized that NSAID exposure may delay the onset of AD 
with younger cohorts showing a reduced frequency of disease and 
older cohorts being enriched for cases that would otherwise have 
appeared earlier.
THE EFFECT OF NSAID TYPE
The type of NSAID also appears to affect the magnitude of the 
protective effect. Generally, the protective effects of NSAIDs are 
higher for users of non-aspirin compounds compared to those 
using aspirin. Users of acetaminophen are not protected (Stewart 
compared to APOE ε4 carriers which did not take NSAIDs) but 
not in those without an APOE ε4 allele (adjusted hazard ratio of 
0.88) (Szekely et al., 2008a). Another prospective study (the Cache 
County Study) that evaluated for 8 years 3,383 elderly subjects 
cognitive normal at baseline, found that NSAID use prior to the 
age of 65 years in subjects with one or more ε4 alleles produced 
the greatest protective effects against cognitive decline evaluated 
with the Modiﬁ  ed Mini-Mental State Examination test (0.40 vs 
0.10 points per year) (Hayden et al., 2007). The MIRAGE Study 
that involved 691 AD patients and 973 family members, showed 
that the protective effects of NSAID use was more pronounced 
among APOE-ε4 carriers than non-carriers (adjusted odd ratios 
of 0.49 and 0.70, respectively) (Yip et al., 2005). In a cohort study 
(the Kungsholmen Project) that evaluated for up to 6 years 1,301 
subjects free of dementia at baseline a reduction of risk of AD 
was seen only in ε4 carriers (relative risk = 0.47) but not in ε4 
 non-carriers (relative risk = 1.08) (Cornelius et al., 2004). Similarly, 
in the Rotterdam cohort study the risk reduction occurred mainly 
in ε4 carriers and not in ε4-non-carriers (relative risks 0.73 and 
0.94, respectively) (in t’ Veld et al., 2001).
The reasons why NSAIDs users with one or more APOE ε4 
allele have a greater AD risk reduction are unclear. In brain, apoE 
is mainly synthesized and secreted by astrocytes and microglia 
(Boyles et al., 1985). Astrocytes and microglia promote Aβ clearance 
and degradation (Koistinaho et al., 2004) via an apoE-dependent 
mechanism (Jiang et al., 2008). Transgenic AD mice expressing 
human APOE-ε4 have lower brain apoE levels and higher brain 
Aβ accumulation than APOE-ε4 non-carriers (Bales et al., 2009). 
Cognitively normal elderly men with APOE-ε4 have higher levels 
Table 1 | Summary of the main prospective and retrospective epidemiological studies of NSAIDs and AD.
Study reference  Overall cohort  Duration NSAID use  AD cases  Risk ratio  95% conﬁ  dence interval
PROSPECTIVE STUDIES
Stewart et al. (1997) 1,686  ≥2 years  81  0.40  0.19–0.84
   <2 years    0.65  0.33–1.29
in t’ Veld et al. (2001) 6,989 ≥2 years  4  0.20  0.05–0.83
   1–23  months  210  0.83  0.62–1.11
   <1 month  88  0.95  0.70–1.29
Breteler et al. (2002) 7,983 ≥18 months  293  0.60  0.30–1.20
Zandi et al. (2002) 3,224  ≥2 years  104  0.45  0.17–0.79
Cornelius et al. (2004) 1,301  NA  164  0.61  0.32–1.15
Haag et al. (2006) 6,992  ≥2 years  582  0.65  0.40–1.06
Szekely et al. (2008a) 3,229 NA  321  0.63  0.45–0.88
Arvanitakis et al. (2008) 1,019  NA  209  1.19  0.87–1.62
Breitner et al. (2009) 2,736 NA  356  1.57  1.10–2.23
RETROSPECTIVE STUDIES
Landi et al. (2003) 2,708  NA  269  0.43  0.23–0.82
Yip et al. (2005) 1,034  >6 months  61  0.64  0.24–0.98
Vlad et al. (2008) 246,199  >5 years  49,349  0.76  0.68–0.85
   >4 to ≤5 years    0.76  0.69–0.84
   >3 to ≤4 years    0.90  0.84–0.97
   >2 to ≤3 years    0.93  0.88–0.99
   >1 to ≤2 years    0.90  0.86–0.94
   ≤1 year    0.98  0.95–1.00
NA: not applicable.Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 19  |  5
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in 1,019 older Catholic clergy followed for up to 12 years did not 
ﬁ  nd a   signiﬁ  cant relationship between NSAID use and incident 
AD, change in cognitive performance or AD neuropathology 
(Arvanitakis et al., 2008).
CLINICAL TRIALS OF ANTI-INFLAMMATORY DRUGS IN 
ALZHEIMER’S DISEASE
The hypothesis that the suppression of the inﬂ  ammatory processes 
underlying the pathological cascade of AD will lessen the rate of 
disease progression and the evidence from epidemiological studies 
suggesting the protective effects of long-term use of NSAIDs against 
the onset of AD formed the rationale for a series of trials of different 
anti-inﬂ  ammatory drugs in AD (Aisen and Davis, 1994).
NSAIDs
The initial pilot studies with NSAIDs produced encouraging results 
(Table 2). A ﬁ  rst 6-month, double-blind, placebo-controlled study 
in 44 AD patients showed a signiﬁ  cant (p = 0.003) slower cog-
nitive decline in patients receiving indomethacin (100–150 mg) 
compared to those on placebo (Rogers et al., 1993). Unfortunately, 
42% of patients abandoned the study due to adverse events (10 on 
indomethacin and 6 on placebo). Thus, the positive results of this 
study are of difﬁ  cult interpretation. A subsequent 1-year double-
blind, placebo-controlled, study of indomethacin (100 mg/day) 
given with omeprazole (20 mg/day) as gastroprotective agent, to 
51 mild-to-moderate AD patients produced relatively low drop-out 
rates (7 out of 26 patients on indomethacin and 6 out of 25 patients 
on placebo) (de Jong et al., 2008). Unfortunately, the low number 
of subjects rendered the study inconclusive with non-  signiﬁ  cant 
trends in favor of indomethacin on two cognitive scales (Alzheimer’s 
Disease Assessment Scale Cognitive Subscale, ADAS-Cog and Mini-
Mental State Examination, MMSE) at 12 months. In another small 
6-month, double-blind, placebo-controlled study in 41 AD patients, 
arithmetic trends were observed in patients   receiving diclofenac 
et al., 1997). In a cohort study of 1,301 dementia-free subjects 
at baseline and followed for 6 years, no subjects who used non-
aspirin NSAIDs for around 3 years developed AD 3 years later 
(Cornelius et al., 2004). The reanalysis of the Rotterdam study 
indicates that risk decrease is restricted to NSAIDs that lower 
Aβ42 (ibuprofen, sulindac, ﬂ   urbiprofen, indomethacin and 
diclofenac) (Breteler et al., 2002; Haag et al., 2006). In a cross-
sectional retrospective study involving 2,708 community-dwell-
ing elderly patients, a signiﬁ  cantly decreased risk of cognitive 
impairment was found for patients using non-aspirin NSAIDs 
(Landi et al., 2003). The lowest adjusted odd ratio for a single 
non-aspirin NSAID drug was observed for diclofenac (0.20). A 
large case-control study evaluated the effects of type of NSAIDs 
used and the duration of the use and found the most signiﬁ  -
cant protective effect is for the for the Aβ42-lowering ibuprofen 
with an odd ratio of 0.56 for greater than 5 year users (Vlad 
et al., 2008).However, the CHS Cognition Study did not ﬁ  nd 
an arithmetic advantage for Aβ42-lowering NSAIDs compared 
to non-lowering ones (adjusted hazard ratios of 0.33 and 0.34, 
respectively), although only in the ﬁ  rst group was the protective 
effect statistically signiﬁ  cant. A pooled analysis of six prospective 
studies involving a total of 13,499 initially dementia-free partici-
pants did not ﬁ  nd an apparent advantage in AD risk reduction 
for the subset of NSAIDs with Aβ42-lowering properties (Szekely 
et al., 2008b).
It is important to point out that not all studies have found that 
NSAID use is associated to a decrease risk of AD. A meta-analysis 
of 25 case-control and cohort studies found that the beneﬁ  t of 
NSAIDs in preventing dementia was 50% in studies with prevalent 
dementia cases, declined to 20% in studies with incident demen-
tia cases, and was absent in studies where cognitive decline was 
used as endpoint (de Craen et al., 2005). Authors concluded that 
most of the reported beneﬁ  cial effects of NSAIDs may result from 
recall bias, prescription bias, and publication bias. Another study 
Table 2 | Double-blind, randomized, placebo-controlled trials of anti-inﬂ  ammatory drugs in patients with mild-to-moderate AD.
Drug  Treatment duration  Dose (mg/day)  No. patients  Main outcome  Reference
Indomethacin 6  months  100–150  44  Beneﬁ  cial effects  Rogers et al. (1993)
Indomethacin 1  year  100  51  Beneﬁ  cial trends  de Jong et al. (2008)
Diclofenac 6  months  50  41  Beneﬁ  cial trends  Scharf et al. (1999)
Nimesulide  3 months  200  40  Neutral effects  Aisen et al. (2002)
Prednisone  1 year  10  138  Neutral/detrimental effects  Aisen et al. (2000)
Dapsone  1 year  100  201  Neutral effects  Bain (2002)
Hydroxychloroquine  18 months  200–400  168  Neutral effects  Van Gool et al. (2001)
Celecoxib  1 year  400  285  Neutral effects  Sainati et al. (2000)
Celecoxib  1 year  400  425  Neutral/detrimental effects  Soininen et al. (2007)
Rofecoxib  1 year  25  351  Neutral/detrimental effects  Aisen et al. (2003)
Rofecoxib  1 year  25  692  Neutral effects  Reines et al. (2004)
Naproxen  1 year  440  351  Neutral effects  Aisen et al. (2003)
Ibuprofen  1 year  800  132  Neutral effects  Pasqualetti et al. (2009)
Tarenﬂ  urbil  1 year  800–1600  210  Neutral effects  Wilcock et al. (2008)
Tarenﬂ  urbil  18 months  1600  1684*  Neutral/detrimental effects  Green et al. (2009)
Tarenﬂ  urbil  18 months  1600  840*  Neutral effects  Wilcock (2009)
*Patients with mild AD.Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 19  |  6
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an accurate examination of the results reveals that the apparent 
positive effects of tarenﬂ  urbil at the dose of 800 mg b.i.d. in mildly 
affected patients were likely due to an anomalous deterioration rate 
observed in patients treated with placebo, rather than to the drug 
itself (Imbimbo, 2009). The apparently positive results of high doses 
of tarenﬂ  urbil in mildly affected AD patients prompted the execu-
tion of the largest ever study in patients with AD that involved 1,684 
mildly affected patients that were treated with tarenﬂ  urbil (800 mg 
b.i.d.) for 18 months (Green et al., 2009). Unfortunately, the study 
came out completely negative with no statistically signiﬁ  cant dif-
ferences on the two primary cognitive and functional variables of 
the study (ADAS-Cog and ADCS-ADL). Paradoxically, patients on 
tarenﬂ  urbil had a signiﬁ  cantly higher deterioration than those on 
placebo on the CDR-SB scale at the end of the 18-month treatment 
period (p = 0.004). Another 18-month study in 840 mild affected 
AD patients conﬁ  rmed that tarenﬂ  urbil does not provide clinical 
beneﬁ  t in this population (Wilcock et al., 2009).
OTHER ANTI-INFLAMMATORY DRUGS
Studies with other anti-inﬂ  ammatory agents produced completely 
negative results (Table 2). A 1-year, double-blind, placebo-controlled 
trial of low doses of prednisone (10 mg daily) in 138 AD patients did 
not show any signiﬁ  cant beneﬁ  t of the glucocorticoid treatment on 
the rate of cognitive decline (Aisen et al., 2000). Actually, patients 
treated with prednisone displayed a greater behavioral decline 
compared with those treated with placebo (p = 0.003 on the Brief 
Psychiatric Rating Scale) and a detrimental trend also on the global 
clinical status (p = 0.07 on the Clinical Dementia Rating Sum of 
Boxes, CDR-SB). An 18-month, randomized, double-blind, place-
bo-controlled study evaluated the ability of hydroxychloroquine, a 
potent anti-inﬂ  ammatory drug widely used in the treatment of rheu-
matoid arthritis and able to cross the blood-brain barrier, to delay 
progression of AD (Van Gool et al., 2001). The study involved 168 
patients and was completed by 92% of participants. Unfortunately, 
at the end of the 18-month treatment period there were no signiﬁ  -
cant differences in any of the efﬁ  cacy outcome measures (activities 
of daily living, cognitive function and behavioral abnormalities). 
A 1-year, randomized, double-blind, placebo-controlled study was 
carried out with dapsone, an old anti-leprosy agent with strong 
anti-inﬂ  ammatory properties and for which a preventive role in 
AD was claimed (McGeer et al., 1992). Dapsone (100 mg/day) and 
placebo were administered orally, once daily for 52 weeks in 201 
patients with mild-to-moderate AD. At the end of treatment there 
were no signiﬁ  cant differences between dapsone and placebo on 
either cognitive or other measures of efﬁ  cacy (Bain, 2002).
PREVENTIVE TRIALS OF NSAIDs IN ALZHEIMER’S DISEASE
Primary and secondary studies have been designed and conducted 
to verify if anti-inﬂ  ammatory drugs are able to prevent the onset of 
AD in patients with mild cognitive impairment (MCI) (Table 3) or 
in healthy elderly subjects at risk of developing AD (Table 4).
A 4-year, double-blind, placebo-controlled study with rofecoxib 
in 1,457 patients with MCI showed that the annual conver-
sion rate to AD was signiﬁ  cantly higher in patients treated with 
rofecoxib (25 mg/day) than in those treated with placebo (6.4% 
versus 4.5%, p = 0.011) (Thal et al., 2005). Another double-blind, 
  placebo-  controlled trial in MCI patients was conducted with 
(50 mg/day) and misoprostol as   gastroprotective agent (Scharf 
et al., 1999). Again, the withdrawal rate was high in the active treat-
ment group (12 of 24 patients vs only 2 of 17 subjects on placebo), 
indicating that AD patients poorly tolerate standard prescription 
doses of NSAIDs. A small and short-term (3 months), placebo-
controlled study of nimesulide, a preferential COX-2 inhibitor, in 
40 AD patients did not show any signiﬁ  cant differences at 12 weeks 
(Aisen et al., 2002).
Studies suggesting that COX-2 may contribute to the neuro-
degeneration occurring in AD brains prompted the concept that 
inhibition of COX-2 might be a useful therapeutic target. COX-2 
inhibitors were initially considered the preferred agents over classic 
NSAIDs, given their better tolerability at full anti-inﬂ  ammatory 
doses. Unfortunately, a 1-year, double-blind placebo-controlled 
study with the COX-2 inhibitor celecoxib (200 mg b.i.d.) failed to 
demonstrate efﬁ  cacy in slowing cognitive decline in 285 AD patients 
(Sainati et al., 2000) (Table 2). Another 1-year study with celecoxib 
(200 mg bid) in 425 mild-to-moderate AD patients did not show 
signiﬁ  cant differences between the COX-2 inhibitor and placebo at 
the end of the 52-week treatment period on either cognitive (ADAS-
Cog) or clinical global (Clinician Interview-Based Impression of 
Change Plus, or CIBIC-Plus) scales (Soininen et al., 2007). There 
were statistically signiﬁ  cant differences in favor of placebo in two 
categories of the patient quality of life scale SF-36 as rated by the 
caregiver at week 52 (Role-Physical, p = 0.022 and Role-Emotional, 
p = 0.043). A 1-year, double-blind, placebo-controlled study in 351 
AD patients comparing the ability of rofecoxib (25 mg once-a-day), 
another COX-2 inhibitor, and naproxen (220 mg twice-a-day) to 
slow cognitive deterioration produced negative results (Aisen et al., 
2003) with cognitive decline (as assessed with ADAS-Cog) being 
actually faster in rofecoxib-treated patients compared to placebo 
(unadjusted p = 0.044). A further even larger study of rofecoxib 
(25 mg once-a-day) was recently completed in 692 patients and did 
not show any signiﬁ  cant difference between rofecoxib and placebo 
after 1 year of treatment (Reines et al., 2004).
Long-term studies with non-selective COX-inhibitors were 
also negative (Table 2). A 1-year, placebo-controlled study in 132 
mild-to-moderate AD patients evaluated the effects of ibuprofen 
(400 mg b.i.d. + esomeprazol 20 mg o.d.) on the cognitive decline 
(Pasqualetti et al., 2009). All patients were receiving stably therapy 
with donepezil. Seventy-seven percent of patients on ibuprofen and 
70% of those on placebo completed the study. Overall, there were 
no effects of ibuprofen on the cognitive and clinical global scales. 
Interestingly, between AD patients carrying one or more ε4 allele, 
those receiving ibuprofen had lower cognitive and clinical decay 
than those that took placebo. The opposite pattern was observed 
in ε4 non-carriers.
A 1-year, placebo-controlled trial with tarenﬂ  urbil (R- ﬂ  urbiprofen) 
in 210 patients with mild-to-moderate AD has produced, overall, 
negative results (Wilcock et al., 2008). The study tested two differ-
ent doses of tarenﬂ  urbil (400 or 800 mg twice-a-day) and patients 
were allowed to take concomitantly cholinesterase inhibitors and/
or memantine. A pre-speciﬁ  ed subgroup analysis revealed that 
patients with mild AD in the 800 mg b.i.d. group had lower rates 
of decline than did those in the placebo group in activities of daily 
living (Alzheimer’s Disease Cooperative Study Activities of Daily 
Living or ADCS-ADL) and global function (CDR-SB). However, Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 19  |  7
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points for celecoxib, p = 0.004 and −0.35 points for naproxen, 
p = 0.06) (ADAPT Research Group, 2008). Masked long-term 
follow-up of the enrolled subjects is ongoing. A recent analyses 
of the 4-year   follow-up data surprisingly revealed that subjects 
previously exposed to naproxen were protected from the onset 
of AD by 67% compared to placebo (Breitner, 2009). The overall 
results of the ADAPT trial suggest that people who already had 
disease process ongoing in their brain (even if asymptomatic) at 
the beginning of the trial indeed worsened if they took NSAIDs, 
which accelerated their underlying disease. In contrast, people 
who had brain completely normal at baseline and took naproxen 
for 1–3 years appeared to fare better. At the long-term examina-
tion, they had a lower incidence of AD than did those on placebo. 
This apparent clinical protection was supported by favorable CSF 
biomarkers values (low tau and high Aβ42 levels) at 21–42 months 
after treatment.
MECHANISMS FOR PROTECTIVE EFFECTS OF NSAIDs IN 
ALZHEIMER’S DISEASE
A number of non-mutually exclusive mechanisms have been pro-
posed to account for the protective effects of NSAIDs in AD. These 
mechanisms are either related to the anti-inﬂ  ammatory properties 
of NSAIDs or are supposed to directly target APP processing, Aβ 
production and Aβ aggregation (Figure 2).
NSAIDs exert their principal therapeutic effects, reducing fever, 
pain and inﬂ  ammation by blocking the COX-mediated synthe-
sis of inﬂ  ammatory PGs (Hoozemans et al., 2008). It is believed 
that NSAIDs may reduce brain inﬂ  ammation in AD through their 
inhibitory effects on COX activity. It has been proposed that the 
beneﬁ  cial effects of NSAIDs on memory in transgenic mouse 
models of AD do not depend upon lowered levels of the inﬂ  am-
matory cytokines, tumor necrosis factor α and interleukin-1β but 
on the blockade of a COX-2-mediated prostaglandin E2 response 
(Kotilinek et al., 2008). Another mechanism that has been impli-
cated in the anti-inﬂ  ammatory action of NSAIDs is the inhibition 
of the activity of the nuclear factor κB (Sung et al., 2004), a tran-
scription factor involved in the regulation of several cellular target 
genes and found to be increased in AD brains. Other studies have 
implicated peroxisome proliferator-activated receptor-γ (PPARγ), 
 triﬂ  usal, a non-selective NSAID (Gómez-Isla et al., 2008). Subjects 
were randomly assigned to receive 900 mg/day of triﬂ  usal or pla-
cebo for 18 months. A slow rate of recruitment forced a premature 
cessation of the study. Two hundred and ﬁ  fty-seven subjects were 
enrolled and followed-up for an average of 13 months. Compared 
to placebo, there was a signiﬁ  cant lower rate of conversion to AD 
in the triﬂ  usal group (hazard ratio = 2.10; 95% conﬁ  dence interval, 
1.10–4.01; p = 0.024). Compared to placebo, there was also a trend in 
favor of triﬂ  usal regarding cognitive decline (ADAS-Cog), although 
the difference did not reach statistical signiﬁ  cance, p = 0.096). 
Because the trial was prematurely halted, these results should be 
interpreted with caution and require further conﬁ  rmation.
Another 18-month, double-blind, placebo-controlled study of 
celecoxib in 88 subjects with mild, self-reported, memory com-
plaints but with normal memory performance score was recently 
published (Small et al., 2008) and reported signiﬁ  cant differences 
in favor of the COX-2 inhibitor on executive functioning (p = 0.03) 
and language/semantic memory (p = 0.02). Signiﬁ  cant differ-
ences in favor of celecoxib were also detected in regional brain 
metabolism measured with FDG-PET in prefrontal cortex. These 
apparently positive cognitive and metabolic results should be con-
sidered with caution because of the high drop-out rate (48 out of 
88 subjects).
A primary prevention trial (ADAPT) was conducted in 2,528 
cognitively normal individuals at risk for AD (age > 70 years and 
ﬁ  rst degree relative with dementia). Subjects were randomized 
to receive naproxen (220 mg twice-a-day) or celecoxib (200 mg 
twice-a-day) or placebo (ADAPT Research Group, 2007). Initially, 
treatments were planned to last 7 years. The main endpoint of the 
study was the onset of AD after randomization. Enrolment began 
in early 2001. On December 17, 2004, treatments were suspended. 
Median follow-up times were 733 days for celecoxib-, 734 days 
for naproxen- and 735 days for placebo-assigned participants. 
Analyses that excluded the seven individuals with dementia that 
were erroneously enrolled in the study, showed increased hazard 
ratios for AD compared to placebo with both celecoxib (hazard 
ratio = 4.11, p = 0.22) and naproxen (hazard ratio = 3.57, p = 0.04). 
After 2 years of treatment, mean scores of the Modiﬁ  ed MMSE of 
both   drug-treated groups were worse than that of placebo (−0.69 
Table 3 | Double-blind, randomized, placebo-controlled trials of NSAIDs in patients with MCI.
Drug  Treatment duration  Dose (mg/day)  No. patients  Main outcome  Reference
Rofecoxib  4 years  25  1,457  Detrimental effects  Thal et al. (2005)
Triﬂ  usal  13 months  900  257  Neutral/beneﬁ  cial effects  Gómez-Isla et al. (2008)
Celecoxib 18  months  200–400  88*  Beneﬁ  cial effects  Small et al. (2008)
*Subjects with age-associated memory decline.
Table 4 | Double-blind, randomized, placebo-controlled primary prevention studies of NSAIDs in AD.
Drug  Treatment duration  Dose (mg/day)  No. patients  Main outcome  Reference
Celecoxib  2 years  400  2,528  Neutral/detrimental effects  ADAPT (2007)
Naproxen  2 years  440  2,528  Neutral/detrimental effects*  ADAPT (2007)
*Beneﬁ  cial effects at 4-year follow-up.Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 19  |  8
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pathway (Avramovich et al., 2002). Furthermore, ibuprofen and 
indomethacin have been shown to reverse elevations in BACE1 
expression and Aβ secretion after stimulation of cell lines with 
pro-inﬂ   ammatory cytokines (Sastre et al., 2006). Ibuprofen 
can reduce expression of α1-antichymotrypsin (α1-ACT), 
an acute phase protein that accelerates amyloid pathology in 
APP-transgenic mice (Morihara et al., 2005). NSAIDs may also 
inhibit Aβ aggregation and ﬁ  bril formation in vitro (Thomas 
et al., 2001). Finally, NSAIDs may act to inhibit the formation of 
Aβ oligomers and deposits through direct interaction with the 
Aβ peptide (Kukar et al., 2008). Human neuropathological stud-
ies have failed to show that NSAID treatment ameliorates brain 
plaque burden in AD patients (Alafuzoff et al., 2000; Halliday 
et al., 2000).
Other mechanisms possibly explaining the protective role of 
NSAIDs in AD include increase in the expression of neurotrophic 
factors (Zhao et al., 2008), regulation of glutamate homeostasis 
(Casper et al., 2000; Khansari and Halliwell, 2009), maintenance of 
synaptic plasticity (Stéphan et al., 2003; Kotilinek et al., 2008).
a nuclear receptor that controls expression of pro-inﬂ  ammatory 
genes, as an alternative mediator of the anti-inﬂ  ammatory prop-
erties of NSAIDs (Sastre et al., 2003). NSAIDs may stimulate 
PPARγ activity with the consequent inhibition of the inﬂ  amma-
tory response. More recently, it has been shown that ibuprofen 
and naproxen are able to blocked neuronal cell cycle events and 
alterations in brain microglia of a transgenic hAPP mouse model 
of AD without altering APP processing and steady-state brain Aβ 
levels (Varvel et al., 2009).
The other hypothesis that has been proposed for explaining the 
beneﬁ  cial effect of NSAIDs in AD is their activity on APP process-
ing, Aβ production or Aβ aggregation. A number of mechanisms 
have been proposed for this action. First, some NSAIDs, includ-
ing ibuprofen and indomethacin, were shown to selectively lower 
Aβ42 production in vitro and in APP-transgenic mouse models of 
AD (Weggen et al., 2001). In addition, it has also been shown that 
ibuprofen and indomethacin potently stimulate secretion of the 
neurotrophic and neuroprotective APP ectodomain in neuronal 
cell lines by up-regulation of the non-amyloidogenic α-secretase 
FIGURE 2 | Potential protective mechanisms of NSAIDs in AD (from Weggen et al., 2007).Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 19  |  9
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THE EFFECTS OF NSAIDs ON ASTROCYTES
In the healthy brain, astrocytes support neurons metabolically and 
functionally. In the AD brain, astrocytes surround plaques and 
might play a critical role in Aβ deposition and clearance, neuronal 
calcium homeostasis and synaptic function and might contribute to 
cortical dysfunction (Kuchibhotla et al., 2009). Reactive astrocytes 
neglect their neurosupportive functions, thus rendering neurons 
vulnerable to neurotoxins including pro-inﬂ  ammatory cytokines 
and reactive oxygen species (Fuller et al., 2009). NSAIDs may 
interact with astrocytes by modulating activation and migration. 
A short-term treatment with ibuprofen of adult APP-transgenic 
mice resulted in a signiﬁ  cant reduction in the number of reactive 
astrocytes in the hippocampus and cortex (Heneka et al., 2005). 
The effects of NSAIDs on number of reactive astrocytes may be 
ascribed to the inhibitory effect on Aβ deposition (Richardson et al., 
2002) but are also due to a direct modulating effect on astrocytes. 
In rat primary cultures, ibuprofen produced profound stellation 
of astrocytes and altered their migration (Lichtenstein et al., 2009). 
In mouse and human astrocyte cell culture ibuprofen reduced 
α1-antichymotrypsin release induced by LPS or IL-1β (Morihara 
et al., 2005). Ibuprofen signiﬁ  cantly reduced NMDA-induced neu-
ronal cell death in mixed cortical cultures containing mice neuronal 
and glial cells but not in near-pure neuronal cultures containing 
less than 5% astrocytes (Iwata et al., 2010). Thus, NSAIDs may 
protect against AD by direct and indirect interaction with reactive 
astrocytes.
NEUROPROTECTIVE EFFECTS OF NSAIDs
Some reports show that NSAIDs may be neuroprotective. A study 
using rat cerebellar granule cell culture showed that sulindac sul-
phide, indomethacin, ibuprofen and R-ﬂ  urbiprofen, at low concen-
trations (1 µM), depolarize mitochondria and inhibit mitochondrial 
Ca2+ overload, cytochrome c release and cell death induced by Aβ 
oligomers (Sanz-Blasco et al., 2008). Ibuprofen has been shown to 
promote neurite growth in neuroblastoma B104 cell line (Dill et al., 
2010) and to promote signiﬁ  cant axonal growth and functional 
recovery following spinal cord lesions in rodents (Fu et al., 2007) 
via a RhoA-PPARγ-mediated mechanism.
WHY DID ANTI-INFLAMMATORY DRUGS FAIL IN ALZHEIMER’S 
DISEASE?
So far, clinical trials designed to inhibit brain inﬂ  ammation in AD 
patients have failed. These failures have been ascribed to wrong 
timing of intervention, to the short duration of treatment, to the 
low doses used and to the wrong class of drugs. However, the real 
problem is that it is still not clear whether or not inﬂ  ammatory 
mechanisms are actually causing damage in AD or whether they 
are merely present to remove the debris from other more primary 
pathological processes. The inhibitory effects of NSAIDs on acti-
vated microglia may play a negative role (Masters et al., 2008). For 
many years microglial activation has been considered to contrib-
ute to AD progression. Recent studies using in vivo imaging have 
demonstrated that microglia rapidly migrate to newly formed Aβ 
deposits in mouse models of AD but are not able to clear them 
but instead tend to stabilize the plaques avoiding further growth 
(Meyer-Luehmann et al., 2008; Bolmont et al., 2008). The initial 
inability of activate microglia of phagocyting ﬁ  brillary Aβ has 
THE EFFECTS OF NSAIDs ON MICROGLIA
The role of microglia in the AD pathogenesis is very much debated. 
Microglial activation adjacent to amyloid deposits in AD has sug-
gested that microglia-induced neuroinﬂ  ammatory  responses 
mediate neurodegeneration (Wyss-Coray, 2006). It has been pro-
posed that cytokines, chemokines and neurotoxins generated by 
Aβ-activated microglia cause neuronal damage (El Khoury and 
Luster, 2008). However, different reports showed that microglia 
or bone marrow-derived macrophages may have a function of 
stimulating Aβ clearance and antagonizing plaque growth (Simard 
et al., 2006; Bolmont et al., 2008; Meyer-Luehmann et al., 2008). 
Conversely, a recent paper has shown that amyloid plaque forma-
tion and maintenance in two transgenic mouse models of AD was 
not inﬂ  uenced by nearly complete ablation of microglia achieved 
with gene manipulation (Grathwohl et al., 2009). Although this 
work showed that microglia ablation does not cause an increase in 
plaque burden, it did not demonstrate that microglia and peripheral 
macrophages are not able to inhibit brain plaque formation or 
clear plaques in vivo. In addition, microglia ablation was induced 
too late in respect to the crucial phase of plaque seeding of the two 
AD transgenic mice. It could be that microglia may damage the AD 
brain before full plaque deposition as suggested by a recent paper 
(Varvel et al., 2009).
Although many animal studies support the notion that 
NSAIDs attenuate microglia activation and inhibit inflam-
matory mediators in transgenic mouse models of AD, data in 
humans are quite scanty. One study in 66 subjects reported that 
brains of non-demented arthritic patients chronically treated 
with NSAIDs has reduced number of activated microglial cells 
than non-demented control subjects (Mackenzie and Munoz, 
1998). On the other hand, another study in 42 AD patients with 
a history of regular use of NSAIDs showed significant lower 
counts of brain reactive astrocytes but not of activated microglia 
(Alafuzoff et al., 2000). A further neuropathological study in 12 
AD subjects failed to show significant differences in number 
of microglia and astrocytes in NSAID users and   non-users 
(Halliday et al., 2000).
Nevertheless, the hypothesis that the beneﬁ  cial effects of NSAIDs 
derive from their action on microglia has been recently reinforced 
in a study employing a reliable transgenic animal model of AD 
(R1.40 mouse) (Varvel et al., 2009). This study showed that altera-
tions in brain microglia were coincident with the ﬁ  rst evidence of 
neuronal cell cycle events, a early pathogenic process in AD (McShea 
et al., 1997; Yang et al., 2001). Interestingly, in R1.40 transgenic 
mice both microglia activation and increased neuronal cell cycle 
events occurred before the onset of Aβ deposition. Induction of 
systemic inﬂ  ammation promoted the early appearance of neuronal 
cell cycle events in young transgenic mice, but not in non-transgenic 
controls. In addition, inhibition of neuroinﬂ  ammation in young 
transgenic animals by chronic administration of ibuprofen and 
naproxen blocked alterations in brain microglia as well as neu-
ronal cell cycle events in the absence of any effect on brain Aβ40 
and Aβ42 levels. Notably, therapeutic NSAID treatment of older 
transgenic mice did not reverse the presence of existing cell cycle 
events, even after several months of treatment. These results provide 
a potential explanation for the failures of the prospective NSAID 
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The failures include both steroidal anti-inﬂ  ammatory agents 
like prednisone, non-steroidal anti-inﬂ   ammatory drugs like 
hydroxychloroquine or dapsone, non-selective COX-inhibitors 
like naproxen as well as COX-2 selective inhibitors like rofecoxib 
and celecoxib. Unfortunately, ibuprofen, the NSAID with the 
clearest ﬁ  ndings in epidemiological studies (Vlad et al., 2008), 
the most promising and consistent results in pharmacological 
studies (Imbimbo, 2004) and one of the better tolerated agent in 
humans (McGettigan and Henry, 2006), has been tested only in 
a relatively small study in AD patients (Pasqualetti et al., 2009) 
but not in patients with MCI.
These negative results may be ascribed to low doses used insuf-
ﬁ  ciently to suppress brain inﬂ  ammatory activity. However, negative 
results were also obtained with a potent anti-inﬂ  ammatory drug 
like prednisone, which paradoxically accelerated clinical deterio-
ration of AD patients (Aisen et al., 2000). It has been argued that 
anti-inﬂ  ammatory therapy cannot protect patients when dementia 
is fully established. However, a large trial in patients with MCI 
indicated that rofecoxib could even accelerate the conversion to 
AD (Thal et al., 2005). In addition, a primary prevention study of 
naproxen and celecoxib in elderly subjects with family history of 
AD has been interrupted prematurely with indications of negative 
or even detrimental effects of the two NSAIDs (ADAPT Research 
Group, 2007, 2008).
The discovery that some NSAIDs selectively decrease Aβ42 by 
allosterically inhibiting the γ-secretase complex, has initially shed 
light on the apparent discrepancy between epidemiological studies 
and negative trials. The inhibition of Aβ42 production is independ-
ent from COX activity and depends on the chemical structure of 
the NSAIDs, some compounds being active (ibuprofen, sulindac 
sulphide, ﬂ  urbiprofen, indomethacin, diclofenac) and others not 
(naproxen, aspirin, meloxicam, celecoxib, rofecoxib). Thus, the 
negative results of the AD trial with naproxen, dapsone, prednisone, 
celecoxib and rofecoxib might be explained by the fact these com-
pounds do not lower Aβ42 production. The encouraging results 
observed in small AD trials with indomethacin and diclofenac 
would be in agreement with their inhibitory activity on Aβ42 
production. The detrimental effects of rofecoxib observed in both 
AD and MCI would also agree with the ability of the compound 
to stimulate Aβ42 production. However, the recent negative results 
of two large 18-month studies with tarenﬂ  urbil (R-ﬂ  urbiprofen) 
have questioned the hypothesis that Aβ42-lowering NSAIDs may 
be clinically efﬁ  cacious in AD patients (Green et al., 2009; Wilcock 
et al., 2009). Nevertheless, tarenﬂ  urbil may not be the right Aβ42 
lowering NSAID derivative because of its weak pharmacological 
activity and poor brain penetration (Imbimbo, 2009). In addition, 
it could be that the compound, even though it is the R enantiomer 
of ﬂ  urbiprofen, still maintains a signiﬁ  cant anti-COX activity at 
the high dose used in the study (800 mg b.i.d.). The occurrence 
of several gastro-intestinal adverse events in AD patients treated 
with tarenﬂ  urbil during the Phase III study, including eight cases of 
peptic ulcer (vs. only one in the placebo group) (Green et al., 2009), 
seems to conﬁ  rm this hypothesis. Evidences or indications of detri-
mental effects compared to placebo have already been observed in 
other large, long-term, controlled studies with anti-inﬂ  ammatory 
drugs, including prednisone (Aisen et al., 2000), rofecoxib (Aisen 
et al., 2003) and celecoxib (Soininen et al., 2007) in AD patients, 
been ascribed to the release of pro-inﬂ  ammatory cytokines that 
follows microglial activation. Thus, initial neuroinﬂ  ammation 
may, in part, underlie the accumulation of ﬁ  brillary Aβ-containing 
plaques within the AD brain (Koenigsknecht-Talboo and Landreth, 
2005). At his initial stage of the disease process, the administration 
of NSAIDs could be beneﬁ  cial for its ability to reduce microglia 
activation and cytokine release. However, chronic microglia activa-
tion may lead to plaque removal (Backsai et al., 2001). In addition, 
bone marrow-derived macrophages, the peripheral counterpart of 
microglia, may migrate in the brain and contribute to removal of 
plaques (Malm et al., 2005). Indeed, bone marrow-derived micro-
glia, but not resident microglia, have been reported to prevent the 
formation and even eliminate brain amyloid deposits (Simard et al., 
2006). Interestingly, the removal of brain soluble and insoluble Aβ 
by bone marrow-derived macrophages is dependent from APOE 
genotype with macrophages expressing apoE2 being more efﬁ  -
cient at degrading Aβ than apoE3-expressing, apoE4-expressing, 
or apoE-deﬁ  cient macrophages (Zhao et al., 2009). A study in mice 
lacking the chemokine receptor 2, a microglial cell-surface receptor 
that mediates recruitment of blood-derived microglia, supports 
the idea that bone marrow-derived macrophages inﬁ  ltrate the 
brain and can clear Aβ from the brain (El Khoury et al., 2007). In 
addition, it has been recently demonstrated that microglia is able 
to internalize soluble Aβ, the most toxic species of Aβ, from the 
extracellular milieu through a macropinocytic mechanism into late 
endolysosomal compartments where they are subject to degrada-
tion (Mandrekar et al., 2009). Thus, the use of NSAIDs in advanced 
stages of AD may be detrimental by inhibiting microglia-mediated 
clearance of Aβ.
Recently, activated microglia has been shown to be involved 
in the regulation of several aspects of neurogenesis under certain 
experimental conditions both in vitro and in vivo (Ekdahl et al., 
2009). Under physiological conditions, microglia remains in a rest-
ing state in the dentate gyrus (Olah et al., 2009). Under pathological 
conditions, there is accumulation of microglia with proneurogenic 
phenotype in the adult rat subventricular zone of the dentate gyrus 
of the hippocampus implying a supportive role of these cells for the 
continuous neurogenesis after damage (Thored et al., 2009). The 
function of neurogenesis in the human hippocampus remains elu-
sive, but growing evidence suggests its importance for memory tasks 
(Shors et al., 2001). Neurogenesis is increased in AD hippocampus 
where it may represent a compensatory phenomenon to replace 
neurons lost during the disease (Jin et al., 2004). In a chronically 
altered environment, persistently activated microglia can display 
protective functions that favor brain repair processes (Cacci et al., 
2008). Indeed, the use of COX-2 inhibitors has been shown to 
attenuate the proliferation of progenitors in the subgranular zone 
after transient forebrain ischemia in adult mouse (Sasaki et al., 
2003). Thus, inhibition of activated microglia by anti-inﬂ  ammatory 
drugs may be detrimental also by interfering with compensatory 
neurogenesis processes.
CONCLUSIONS
Despite epidemiological evidences and an apparently robust 
biochemical rationale, all large, long-term, prospective, rand-
omized, placebo-controlled studies aimed to reduce inﬂ  amma-
tion in the brain of AD patients have produced negative results. Frontiers in Aging Neuroscience  www.frontiersin.org  May 2010  | Volume 2  |  Article 19  |  11
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Cohort study  epidemiological study in which individuals 
with differing exposures to a suspected factor are identiﬁ  ed and 
then observed for the occurrence of certain health effects over 
some period.
Prospective study  cohort study in which the subjects are identi-
ﬁ  ed and then followed forward in time.
Longitudinal study  cohort study that involves repeated observa-
tions of the same items over long periods of time.
Case-control study  epidemiological study which compares the 
frequency of a purported risk factor (generally called the “expo-
sure”) in a group of people (the “cases”) affected by a medical 
condition of interest and a group of individuals (the “controls”) 
who are not affected but are otherwise similar.
Retrospective study  a study that starts after the onset of disease 
and looks back to the postulated causal factors.
Primary prevention study  a study including general or healthy 
populations.
Secondary prevention study  a study including participants with 
speciﬁ  c disease.
Cross-sectional study  a study which disease and exposure status 
are measured simultaneously in a given population.
Incident cases  number of new cases of the disease occurring in 
the population in a given period of time.
Relative risk  ratio of the probability of the event occurring in 
the exposed group versus a non-exposed group.
Odds  ratio of the number of people incurring an event to the 
number of people who have non-events.
Odds ratio  odds in favor of being exposed in subjects with the 
target disorder divided by the odds in favor of being exposed in 
control subjects.
Systematic review  a study of the literature that tries to identify, 
appraise, select and synthesize all high quality research evidence 
relevant to that question.
Adjustment  statistical technique that estimates the association 
between an exposure and an outcome while “controlling” (“adjust-
ing”) for one or more possible confounding variables.
Hazard ratio  a measure of the frequency of occurrence of an 
event in one group compared to that occurring in another group, 
over time.
Population-based study  a study involving a subset (or sample) 
of individuals selected from a larger group (population).
Meta-analysis  a systematic review that uses quantitative methods 
to summarize the results.
Prevalent cases  number of cases of the disease in the population 
at a given time.
Randomized clinical trial  a clinical study that compares the efﬁ  -
cacy of two or more drugs or medical interventions in which the 
different treatments are randomly allocated to subjects.
rofecoxib in patients with MCI (Thal et al., 2005), celecoxib and 
naproxen in elderly subjects at risk of developing AD (ADAPT 
Research Group, 2007, 2008).
These negative and even detrimental effects of NSAIDs in 
patients with AD or MCI and in subjects at risk of AD appear to 
be in contrast to the epidemiologic ﬁ  ndings suggesting reduced 
AD incidence following prolonged NSAID use. A possible expla-
nation is that the effects of NSAID exposures differ with the stage 
of brain disease progression. NSAIDs suppress brain inﬂ  amma-
tory mechanisms, particularly the secretion by activated micro-
glia of cytokines and chemokines that are believed to promote 
AD pathogenesis. However, it is likely that NSAID suppression 
of microglial activation might exert protective effects only when 
given years before the development of clinical symptoms. Once the 
pathological brain deposition of Aβ is started, microglia activation 
may be essential to boost the clearance of the excess of toxic amy-
loid. At this stage, when clinical symptoms start to become evident, 
NSAID suppression of microglial activity could be not beneﬁ  cial 
or could even be detrimental by accelerating the disease process. 
This hypothesis appears to be consistent with data from both the 
Rotterdam (Szekely et al., 2004), the Cache County (in t’ Veld et al., 
2001) and the US Veterans (Vlad et al., 2008) observational stud-
ies. All these studies suggest no protection with NSAIDs used in 
the 2 years preceding the onset of dementia. If timing of exposure 
determines whether NSAIDs produce beneﬁ  t or harm, the negative 
results of the prematurely interrupted primary prevention study 
with naproxen and celecoxib (ADAPT study) should not be sur-
prising because subjects were exposed to NSAIDs for only 2 years. 
According to this hypothesis, NSAIDs may prevent AD if given 
years before the typical onset age, but may increase risks when used 
later in life. Since the observational studies suggest that NSAIDs 
may have protective effects only in subjects with a normal brain, 
continued observations in the ADAPT cohort could show mitiga-
tion or even reversal of treatment effects that presently appear null 
or detrimental. Recent results at 4 years of the masked   long-term 
follow-up of the ADAPT study, showing a robust reduction in 
AD risk in subjects exposed to naproxen (Breitner, 2009), seem to 
conﬁ  rm this hypothesis. Thus, long-term trials with NSAIDs or 
NSAIDs-derivatives (Imbimbo et al., 2007) in cognitively normal 
APOE ε4 carriers appear rationale. On the other hand, we cannot 
exclude the possibility that most of the reported beneﬁ  cial effects of 
NSAIDs in epidemiological studies may result from various forms 
of bias (de Craen et al., 2005) and that there is in fact no role for 
NSAIDs in AD prevention or treatment.
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